Replies to post #124027 on Biotech Values

[Double_Bagel]

At what point would TEVA start to get interesting even with the threat of generic copaxone and no Teva Lovenox? At $40? At $35? Sure I would like to see it go really low as punishment for the headaches they have caused to MNTA investors. But at some point TEVA has got to look be a bargain, right? Thanks.

These are not happy days for Teva. If their executives hadn’t been such schmoes with respect to Lovenox, the investment community might have been willing to give them the benefit of the doubt on their overall sales and earnings guidance for 2011 and beyond.